Duodenal Diseases

09/01/1981 - "[Reflexion on cimetidine use to treat oesogastro-duodenal diseases (author's transl)]."
10/01/1979 - "Both cimetidine and antacids produced a near elimination of duodenal disease and markedly reduced the severity of gastric disease when compared to that of untreated historical controls. "

10/01/1979 - "Both cimetidine and antacids produced a near elimination of duodenal disease and markedly reduced the severity of gastric disease when compared to that of untreated historical controls. "

01/01/2007 - "In five peptic acid gastro/duodenal disease was confirmed and the rest had drugs without specific indication, demonstrating suitable morphology of the SEGD intervention. "
03/01/1976 - "Acid output was not predictive of disease; acute duodenal ulcers, however, were not discovered in patients with acid secretion of less than 3.11 mEq/hr. Patients with both gastric and duodenal disease secreted significantly (P less than .05) more acid than patients without duodenal involvement and complications were more likely to develop, especially from acute ulcerations. "
03/01/2001 - "pylori-related inflammation in antrum, in association with a nonatrophic corpus mucosa--of which phenotype is the most common--and with an increased risk of peptic ulcer disease, duodenal ulcer in particular ("duodenal ulcer phenotype" of gastritis); the presence of atrophic gastritis in corpus of the stomach ("corpus predominant gastritis"), which indicates a low risk of peptic ulcer and a reduction in the capacity of the patient to secrete acid; the occurrence of advanced atrophic gastritis and intestinal metaplasia multifocally in the stomach (advanced "multifocal atrophic gastritis"), which are features of a gastritis type and which also indicate a low acid secretion capacity and an increased risk of gastric neoplasias ("gastric cancer phenotype of gastritis"), suggesting a need for a careful exclusion of concomitant presence of small focal neoplastic or dysplastic lesions; and the presence of normal and healthy gastric mucosa, which indicates an extremely low risk of both peptic ulcer disease or gastric cancer and, therefore, is a finding of high clinical relevance. "
01/01/2007 - "[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors]."
06/19/2003 - "Proton pump inhibitors (PPIs) are today used at different recommended doses for treatment of acid-related gastro-esophageal, gastric and gastro-duodenal diseases. "

01/01/2007 - "[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors]."
05/01/1998 - "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials. "

06/19/2003 - "Proton pump inhibitors (PPIs) are today used at different recommended doses for treatment of acid-related gastro-esophageal, gastric and gastro-duodenal diseases. "
05/01/1998 - "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials. "

11/01/1987 - "In order to study the lysozyme activity in the cystic mucosal and submucosal glands in the stomal area of the gastric remnant, which is one of the components of gastritis cystica polyposa, we carried out a pathological and immunohistochemical examination of 55 patients with gastric remnants, including 19 with stomal carcinoma, after partial gastrectomy for benign gastro-duodenal diseases. "

12/01/2002 - "We aimed to study the possible correlation between erosive oesophageal and gastro-duodenal diseases in patients with or without erosive oesophagitis who are taking low-dose aspirin, or simple analgesics, or those infected with. "

12/01/2002 - "We aimed to study the possible correlation between erosive oesophageal and gastro-duodenal diseases in patients with or without erosive oesophagitis who are taking low-dose aspirin, or simple analgesics, or those infected with. "

10/01/1983 - "In order to evaluate its clinical usefulness, serum pepsinogen I level was measured in a prospective study in unselected patients affected by endoscopically and histologically confirmed gastric or duodenal diseases. "
02/01/1983 - "[Clinical significance of serum group I pepsinogen level in gastric duodenal diseases]."
11/01/1995 - "[Serum pepsinogen response to therapy for Helicobacter pylori associated gastro-duodenal disease]."

06/01/1991 - "[Glucagon and prostaglandins in stomach and duodenal diseases]."
07/01/1986 - "Rabbits immunized against prostaglandins develop antibodies to prostaglandins and peptic ulcer disease (duodenal and gastric ulcers). "

01/01/2022 - "Gastroscopy and mucosal biopsy are the gold standard methods for diagnosing gastric and duodenal diseases, but they are invasive procedures and carry risks due to the necessity of sedation and anesthesia. "

01/01/1989 - "Sixteen gastrectomies (25%) were necessary because of the severity of the duodenal disease with a significantly higher rate in the case of post-bulbar ulcers. "
05/01/2000 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "
01/01/1998 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "
11/01/1987 - "In order to study the lysozyme activity in the cystic mucosal and submucosal glands in the stomal area of the gastric remnant, which is one of the components of gastritis cystica polyposa, we carried out a pathological and immunohistochemical examination of 55 patients with gastric remnants, including 19 with stomal carcinoma, after partial gastrectomy for benign gastro-duodenal diseases. "

06/01/1988 - "A follow up was performed in 109 patients primarily undergone Billroth II resection for benign gastric or duodenal diseases to analyze mucosal changes, possibility of premalignant lesions and importance of causal factors in aetiology of gastric stump cancer. "
05/01/2000 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "
01/01/1998 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "

05/01/2000 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "
01/01/1998 - "The study was performed in 172 patients: with gastric and duodenal ulcer, after Billroth I and Billroth II gastrectomy, with gastroesophageal reflux, after cholecystectomy, with chronic cholecystitis and chronic duodenal disease. "

04/01/1986 - "[Clinico-diagnostic importance of instrumental study methods and the problems of the pathogenetic therapy of chronic stomach and duodenal diseases in children]."
09/01/2001 - "In the multivariate analysis the duration (6 vs. 12 days) of eradication therapy (odds ratio: 2.2; 1.3-3.7) and the type of disease (duodenal ulcer vs. non-ulcer dyspepsia; odds ratio: 2.3; 1.3-3.8) were the only variables which influenced on H. "
12/01/2017 - "Helicobacter pylori eradication therapy improves the healing of various gastro-duodenal diseases such as chronic gastritis and peptic ulcer, and also reduces gastric cancer incidence. "
11/01/1995 - "pylori therapy on serum concentrations of pepsinogens on 87 patients of gastro-duodenal disease. "
11/01/1995 - "[Serum pepsinogen response to therapy for Helicobacter pylori associated gastro-duodenal disease]."